CAR T cell therapy for solid tumors: Fatal attraction requires adhesion

Med. 2022 Jun 10;3(6):353-354. doi: 10.1016/j.medj.2022.05.009.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors in clinical studies in contrast to hematological malignancies. In a paper recently published in Nature, Larson et al. report that CAR T cell activity against solid tumors depends on cell adhesion mediated by IFNγ signaling, opening the prospect of improving their clinical activity in the future.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Hematologic Neoplasms* / metabolism
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Neoplasms* / therapy
  • Receptors, Antigen, T-Cell / genetics
  • T-Lymphocytes

Substances

  • Receptors, Antigen, T-Cell